For instance, despite human mesenchymal stem cells being utilized in IPF therapy for their immune regulatory properties, recent animal studies have revealed that administering PD1/PDL1 inhibitors can reverse their antifibrotic effect (117, 118). Here, PDCD1 is linked to idiopathic pulmonary fibrosis.